Kornimate/medical-research-clean huggingface dataset:
preventing suicide with safe alternatives for teens and youths (safety)

Conditions: Suicide and Self-harm

Summary: suicide is the leading cause of death in the age span 10-19 years in sweden. the most robust predictor of future suicide attempt and suicide death is prior suicide attempt. yet, most youths presenting with suicidal behavior to the child and adolescent mental health services (camhs) in stockholm, sweden are not offered evidence-based care directly targeting suicide risk. safe alternatives for teens and youths (safety) is a novel scalable suicide prevention program designed to fill this critical gap. safety is a cognitive behavioral family treatment incorporating elements from dialectical behavior therapy and multisystemic therapy. safety has shown promise in reducing suicide attempts in two small-n trials. in a randomized controlled feasibility trial, the investigators will examine the feasibility of safety and an active control condition named supportive therapy at post-treatment, 3 and 12 months after treatment on youth suicidal behavior. evaluations of feasibility, acceptability, and safety based on data from this pilot trial will guide and inform the design of a full-scale randomized controlled trial.

research questions: 1. is it feasible (operationalized as participation in treatment, completed homework assignments, reported adverse events) to offer safety to youths with suicidal behavior and their caregivers within the camhs? 2. is it feasible (operationalized as participation in treatment, completed homework assignments, reported adverse events) to offer supportive therapy as an active control treatment to youths with suicidal behavior and their caregivers within the camhs? 3. is the planned procedure and design (recruitment, blinded assessors, randomization and data attrition) of the study feasible? 4. what are the proportions of suicidal behavior in the group randomized to safety group and the group randomized to supportive therapy, respectively? 5. is participation in safety and supportive therapy associated with improved emotion regulation, perceived social support, and family function, and how large are the effects (suggested treatment processes)? 6. is participation in safety and supportive therapy associated with improvements in nonsuicidal self-injury, depression, anxiety, and other outcomes, and how large are the effects (outcomes)? 7. how do the youths and caregivers experience participation in safety and supportive therapy, respectively?

Eligibility criteria:
inclusion criteria: * suicidal behavior (defined as suicide attempt, interrupted suicide attempt, aborted suicide attempt, or preparatory behavior) in the last 3 months * age 10-17 years * at least one primary caregiver willing to participate in treatment exclusion criteria: * symptoms requiring other immediate treatment (e.g. psychosis, severe anorexia nervosa) * ongoing treatment with dbt * individual or life circumstances that could complicate or make treatment participation impossible, or that require immediate intervention (e.g., violence in close relationships; intellectual disability) * insufficient understanding of the swedish language
endoscopic ruler for the assessment of variceal bleeding risks (chess2005)

Conditions: Liver Cirrhosis; Portal Hypertension; Gastroesophageal Varices

Summary: the presence of varices is a serious complication of portal hypertension in liver disease. to prevent variceal haemorrhage, screening and surveillance aims to detect high-risk varices related to varices size and determine the need for primary prophylaxis. varices size evaluated by endoscopists might not be perfect reference, influenced by experience and machine. endoscopic ruler is a novel tool to measure the varices size under the endoscopy. the investigators aim to evaluate the bias of varices size between endoscopists and endoscopic ruler as the reference.


Eligibility criteria:
inclusion criteria: * age between 18 and 75 years * clinically evident or biopsy-confirmed cirrhosis * varices diagnosed by endoscopy * written informed consent exclusion criteria: * red sign * active upper gastrointestinal bleeding

Keywords: esophagogastroduodenoscopy endoscopic ruler varices size
assessing coronary non-culprit plaque early with start of pcsk9 inhibitors in acute myocardial infarction (access-ami)

Conditions: Acute Myocardial Infarction

Summary: this study is planned to start on january 2024. the goal of this clinical trial is to learn whether the perioperative administration (within 24 hours before or after primary pci) of pcsk9 inhibitors can ameliorate plaque progression and adverse outcomes in patients with acute myocardial infarction (ami). the main questions it aims to answer are: can perioperative pcsk9 inhibition improve the plaque stability and inflammation of perivascular adipose tissue (index of plaque attenuation（ipa ）and perivascular fat attenuation index（fai）) of non-target lesions? researchers will compare pcsk9 inhibitors with statin plus ezetimibe therapy to evaluate the potential of pcsk9 inhibitors in mitigating the progression of non-target lesion plaques and reducing adverse cardiovascular events in patients with ami. participants will: take pcsk9 inhibitors every two weeks or daily statin plus ezetimibe therapy. conduct a follow-up examination with optical coherence tomography (oct) or coronary computed tomography angiography (cta) after 12 months. record the occurrence of major adverse cardiovascular events.


Eligibility criteria:
inclusion criteria: 1. age ≥18 years old. 2. admitted to hospital for acute myocardial infarction (stemi, nstemi) and successfully underwent pci of the infarct vessel. 3. coronary angiography revealed two non-infarct-related arteries with non-blocking lesions (diameter stenosis of 40-70%). 4. able to sign informed consent. 5. willing to undergo 1-year follow-up. exclusion criteria: 1. left main artery disease or severe coronary artery calcification; 2. hemodynamic instability or uncontrolled arrhythmia; 3. history of coronary artery bypass; 4. severe renal insufficiency, active liver disease or liver insufficiency, hematological disease, metabolic or endocrine dysfunction, systemic infection, active malignant tumor and other potentially life-threatening diseases, or the expected survival time is \< 1 year; 5. received any pcsk9 inhibitor treatment within the previous 3 months; 6. pregnant or nursing women or women planning pregnancy; 7. the researcher determined that it was not suitable for inclusion in the group.

Keywords: acute myocardial infarction pericoronary artery fat attenuation index index of plaque attenuation pcsk9 inhibitor
avandia with glyburide in african american and hispanic patients with type 2 diabetes not controlled by glyburide alone

Conditions: Diabetes Mellitus, Type 2

Summary: this study was designed to evaluate the safety and efficacy of avandia (rosiglitazone) (8mg once daily) in african american and hispanic patients with type 2 diabetes mellitus. as microvascular and macrovascular disease are significant contributors to diabetes morbidity and mortality and previous studies suggest that the thiazolidinedione compounds could have potentially beneficial vascular effects, the effects of rosiglitazone therapy on serum parameters associated with endothelial dysfunction, vascular inflammation and impaired fibrinolysis were examined in this study. improvement in these parameters suggests that rosiglitazone may provide an additional beneficial vascular effect, apart from its ability to improve glycemic control.


Eligibility criteria:
inclusion criteria: * african american or hispanic. * type 2 diabetes mellitus. * fpg\>=140mg/dl plus hba1c\>=7.5% whilst receiving su monotherapy. exclusion criteria: * patients who use insulin. * clinically significant liver, kidney or heart disease, including high blood pressure.

Keywords: rosiglitazone glyburide type 2 diabetes mellitus african american hispanic
effect of self-administered tdcs in patients with mdd

Conditions: Major Depressive Disorder

Summary: in this randomized, single-blinded clinical trial, 58 patients with major depressive disorder were assigned to active and sham tdcs stimulation groups in a 1:1 ratio, and treatment responses were evaluated biweekly over six weeks.

patients were randomized to receive either real or sham-tdcs as well as anti-depressant drugs. tdcs was applied over the left (anode) and right (cathode) dorsolateral prefrontal cortex (dlpfc). patients visited the hospital to get tdcs administrations 5 days a week for 2 weeks. they were evaluated every 2 weeks.

Eligibility criteria:
inclusion criteria: * has a diagnosis of a major depressive disorder as confirmed by the scid-iv and mini (without psychotic features) * greater than 22 points of montgomery-asberg depression rating scale * aged 19 to 65. * has provided informed consent * has received escitalopram as a combined antidepressant during the study period exclusion criteria: * has other mental disorders diagnosed by axis-i, except major depressive disorder (however, subject who is diagnosed as both major depressive disorder as well as anxiety disorder can participate the study.) * history of suicidal attempt in the last 6 months * diagnosed with bipolar or psychotic major depressive disorder * diagnosed with other depressive disorders: dysthymic disorder, and depressive disorders that are not elsewhere classified. * has hypersensitivity to escitalopram ingredients * a score of 5 or greater for the question #10 in madrs * diagnosed with closed angle glaucoma or has a history of glaucoma. * history of participation in other clinical trials within 30days. * a major and/or unstable medical or neurologic illness * currently taking substances pimozide * pregnant or has a positive pregnancy serum test.
canadian, multi-centre study of symptom burden and clinical management in subjects with gerd

Conditions: GERD

Summary: this is a cross-sectional study of symptom burden and clinical management. a subset of patients who have attended the primary care (pc) office with reflux symptoms during a retrospective period of 4 months (index visit) are invited to complete health survey questionnaires and partake in a subject-physician/study nurse interview (visit 1), in order to assess the type, intensity and frequency of gerd symptoms at both visits and describe the treatment provided. additionally, the impact of gerd on subjects' life, productivity and willingness to pay for gerd symptom relief will be explored. this design will give a "real-life" clinical practice picture in a representative population of pc doctors and subjects.


Eligibility criteria:
inclusion criteria: * provision of informed consent * ability to complete pro instruments (non-applicable to "non-attendees") * subject with gerd symptom(s). at least presence of troublesome heartburn and/or regurgitation even if not specifically recorded at the index visit. * at least one visit during the retrospective visit period (-6 to -2 months prior to study start). in the reasons for the index visit section of the medical record mention of acid regurgitation and/or heartburn symptom(s) or gerd diagnosis or gerd complications has to be explicit or a treatment decision (prescription) in a previously diagnosed subject although no mention of symptoms is made. exclusion criteria: * prophylactic ppi use to reduce the risk of ulcers in subjects being treated with nsaids * ppi treatment to heal an ulcer induced by nsaid treatment * ppi treatment for h-pylori eradication * participation in any other clinical study in the time window between the index visit and visit 1
comprehensive analysis of nutritional parameters in patients with idiopathic achalasia: a prospective study.

Conditions: Weight Gain; Nutritional Imbalance

Summary: a total of 100 patients aged 18-60 years with confirmed diagnosis of achalasia cardia will be recruited prospectively. in this study, patients diagnosed with achalasia cardia (prior to per oral endoscopic myotomy treatment) will undergo comprehensive evaluation of their nutritional status. all the participants will be asked about the details enlisted in pre-tested proforma.the evaluation will include demographic data(age, gender, food preferences, socio economic status,underlying diseases such as hypertension diabetes mellitus etc) anthropometric assessment (height, weight, body mass index, weight loss and duration, percentage weight loss, midupperarm circumference , triceps skin fold, hand grip strength) and biochemical assessment (hemoglobin, serum albumin and serum pre-albumin,total protein, serum vitamin d, calcium, b12, serum iron). each patients' dietary habits will be assessed by subjective global assesment questionnaire (weight change, dietary intake, gastrointestinal symptoms, functional capacity, oedema, subcutaneous fat,muscle wasting, ascites.the obtained data will be statistically analyzed and interpreted. as we are in the midst of covid-19 pandemic, we will be taking utmost safety precautions to prevent cross-infection. the doctor performing the study and the accompanying technician will be donning the personal protection equipment all throughout the study.

1. .study design: this study is a prospective single arm observational study. 2. .study period: jan 2021-may 2021. 3. sample size: 100 participants. inclusion criteria: 1. male and female patients aged 18-60 years with confirmed diagnosis of idiopathic achalasia. 2. patients who are co-operative, can communicate verbally and willing to give informed consent. exclusion criteria: 3. chronic diarrhea, malignancy, severe comorbid illness affecting the nutritional status 4. previously treated and asymptomatic cases with achalasia

Eligibility criteria:
inclusion criteria: 1. male and female patients aged 18-60 years with confirmed diagnosis of idiopathic achalasia. 2. patients who are co-operative, can communicate verbally and willing to give informed consent. exclusion criteria: 1. chronic diarrhea, malignancy, severe comorbid illness affecting the nutritional status 2. previously treated and asymptomatic cases with achalasia
computer aided tool for diagnosis of neck masses in children

Conditions: Neck Mass; Thyroglossal Duct Cysts; Branchial Cleft Anomalies; Dermoid and Epidermoid Cysts; Infantile Hemangiomas; Teratomas

Summary: the aim of this study was to evaluate the diagnostic efficacy of computer aided diagnostic tool for neck masses using machine learning and deep learning techniques on clinical information and radiological images in children.

this study is a retrospective-prospective design by west china hospital, sichuan university, including clinical data and radiological images. a retrospective database was enrolled for patients with definite histological diagnosis and available radiological images from june 2010 and december 2020. the investigators have constructed deep learning and machine learning diagnostic models on this retrospective cohort and validated it internally. a prospective cohort would recruit patients found neck masses since january 2021. the proposed computer aided diagnostic models would also be validated in this prospective cohort externally. the aim of this study was to evaluate the diagnostic efficacy of computer aided diagnostic tool for neck masses using machine learning and deep learning techniques on clinical data and radiological images in children.

Eligibility criteria:
inclusion criteria: * age up to 18 years old * receiving no treatment before diagnosis * with written informed consent exclusion criteria: * clinical data missing * unavailable radiological images * without written informed consent
amg 102 plus ecx for unresectable locally advanced or metastatic gastric or esophagogastric junction cancer

Conditions: Esophagogastric Junction Adenocarcinoma; Gastric Cancer; Esophageal Cancer

Summary: study phase: 1b/2 indication: previously untreated subjects with unresectable locally advanced or metastatic gastric or esophagogastric junction adenocarcinoma. primary objective(s): part 1: to identify safe dose levels of amg 102, up to 15 mg/kg q3w, to combine with ecx. part 2 (phase 2-double-blind): to estimate with pre-specified precision the effect of the addition of amg 102 to ecx on progression free survival (pfs).


Eligibility criteria:
inclusion criteria: * pathologically confirmed unresectable locally advanced or metastatic gastric or esophagogastric junction (egj) adenocarcinoma; tumors of the distal esophagus within 5 cm of the egj are eligible * ecog performance status 0 or 1 * male or female ≥ 18 years of age exclusion criteria: * previous systemic therapy (chemotherapy or biologic therapy) for locally advanced or metastatic gastric or esophagogastric adenocarcinoma * less than 6 months have elapsed from completion of prior neoadjuvant or adjuvant chemotherapy or chemoradiotherapy. * subjects with resectable disease or suitable for definitive chemoradiation * subjects with persistent gastric outlet obstruction, complete dysphagia or feeding jejunostomy * tumors of squamous cell histology * known central nervous system metastases * clinically significant upper gastro-intestinal bleeding ≤ 30 days prior to enrollment or randomization * serious or non-healing wound

Keywords: locally advanced metastatic
paromip pilot study parodontites & microbiota periodontal

Conditions: Periodontitis

Summary: a new classification of periodontal diseases was created in 2018. the investigators want to know if this clinical classification is based, or not, on a biological reality. to do this, the investigators will collect data from the clinical examination (clinical assessment and radiological assessment) as well as non-invasive samples of subgingival plaque and crevicular gingival fluid (cgf). the subgingival plaque samples will be analyzed to define the microbiotic profiles of the patients and the cgf determined to define their inflammatory expression profiles. these results will then be linked to the diagnosis of severity of periodontitis.

in the new classification of periodontal disease, the investigators will seek to know whether there is a specific bacterial signature associated with the severity of damage on the one hand, and the other hand, the investigators will search for cytokinic biomarkers which can be correlated with the severity of the damage. in this study, the investigators propose to include 25 patients with periodontitis stage i and ii versus stage iii and iv according to chicago classification (2018)

Eligibility criteria:
inclusion criteria: * men and women speaking and understanding french * aged over 18 * with generalized periodontitis (more than 30% of affected sites) * requiring non-surgical periodontal therapy * with a minimum of 12 teeth (3 per quadrant), fitted or not * having given his oral consent to participate in the study * having given his written consent to participate in a biocollection exclusion criteria: * less than 12 teeth present (3 teeth per quadrant) * presence of acute oral lesions (periodontal abscesses, endodontic abscesses, infectious or mycotic lesions...) * presence of ulcerative-necrotic gingivitis or periodontitis * presence of endo-periodontal lesions * chronic or systemic pathology or treatment that can influence the periodontal microbiota : immunotherapy, corticosteroid therapy, biotherapy, unbalanced diabetes, acute inflammatory rheumatism, neurological impairment... * antibiotic during the 3 month preceding inclusion * psychological or linguistic disability preventing good understanding of the study * minors * major patients under legal protection * patients deprived of their liberty * pregnant or lactating woman * patient not affiliated to a health insurance scheme

Keywords: subgingival microbiota chronic periodontitis dysbiosis deep sequencing gingival crevicular fluid
feasibility of a yoga- and mindfulness-based intervention for resident physicians

Conditions: Burnout, Professional; Anxiety; Depression; Stress

Summary: the investigators aim to initiate and complete the first investigation of the effect of a yoga-based program on resident physicians' psychological health using a randomized controlled trial to assess feasibility of the program in this population and measure outcomes across several domains. to meet the goals of the proposed project the investigators have identified 3 specific aims: specific aim 1: assess the acceptability and feasibility of the yoga program through measuring participation and conducting standardized interviews with a subset of yoga participants. specific aim 2: evaluate the effect of the yoga program on resident physicians' stress, burnout, resilience, mindfulness, mood, depression, anxiety, and sleep quality using quantitative self-report measures. specific aim 3. examine whether outcome measures were perceived as relevant to the participants' work environment and were not burdensome as to the length and content of the program.

the project will implement a single group mixed-methods randomized controlled trial to investigate the impact of the 6-week rise program on psychological health in longwood medical area residents. the rise program is an existing standardized yoga program at kripalu that will be adapted for residents in a 60-90-minute, once-weekly class for six weeks. participants will be randomized to either the rise yoga program or a no-treatment control group. participants randomized to the rise program will also be instructed to maintain a short 10-15-minute daily home yoga practice. sessions will be lead by experienced instructors from kripalu and will be held in the longwood medical area. self-report outcomes will be assessed at baseline, at program completion (post-program), at 2-month follow-up, and at 6-month follow-up. participants will include resident physicians at longwood medical area hospitals. the only exclusion criterion is having practiced yoga, meditation, tai chi, qigong, or another mind-body practice at least 25 hours or more in the past 6 months. participants must be willing not to practice mind-body programs other than the treatment protocol during the intervention. we plan to enroll up to 200 participants with a goal of at least 60 participants with a 2:1 ratio of participants randomized to yoga to participants randomized to control. the control group will receive one session of rise after their participation in the trial is complete.

Eligibility criteria:
inclusion criteria: * individuals enrolled in residency programs at brigham and women's hospital, beth israel deaconess, boston children's hospital, or a harvard combined residency program * individuals must be willing to not practice mind-body programs other than the intervention during the treatment protocol * must be proficient in english exclusion criteria: * individuals who currently practice yoga, meditation, tai chi, qigong, and other mind-body practices more than 25 hours in the past 6 months

Keywords: yoga mindfulness meditation resident residency
immunoblotting and goldmann-witmer coefficient for ocular toxoplasmosis

Conditions: Ocular Toxoplasmosis

Summary: ocular toxoplasmosis (ot) is a common cause of posterior uveitis worldwide. the diagnosis of ot is based on clinical findings, but in most cases, laboratory tests are required to confirm the etiology, especially when other diseases are suspected. the aim of this study was to evaluate which methods, between the goldmann-witmer coefficient (gwc) and immunoblotting (ib) with both igg and iga, in aqueous humour (ah) samples, can be the most sensitive to diagnose ot, in current practice, especially in the first three weeks.

goldmann-witmer coefficient (gwc): compares the levels of intraocular antibody (igg) production to that serum, as measured by elisa. gwc = (level of specific igg in aqueous humour/level of specific igg in serum)/(total igg in aqueous humour/total igg in serum) 0.5 to 2: no intraocular antibody production, 2 to 4: suggestive of intraocular antibody production, \> 4: diagnostic of intraocular antibody production to a specific microbial pathogen

Eligibility criteria:
inclusion criteria: * patients who had underwent aqueous humor and serum sample for ocular toxoplasmosis diagnosis exclusion criteria: * immunocompromised patients